A lot of people would be in the same boat as you and I'm sure a fair whack have sold also. Don't want to pollute this thread talking about another company but I will say what's happened to VIT and now BXN will also happen to ECS this year. There is a lot of strength in the underlying business that they weren't capitalising on because they restricted themselves to B2B domestically which meant they handicapped themselves to however much their business customers could sell to their patients (which wasn't a lot due to their partner clinics having low patient numbers). The shackles are well and truly off now and OzSun was one of the top 10 best selling products in Australia in January. You didn't hear that last part from me.
BXN Price at posting:
4.9¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)